A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with 89Zr/131I‐Labeled Tinurilimab
Abstract Lung adenocarcinoma (LUAD) constitutes a major cause of cancer‐related fatalities worldwide. Early identification of malignant pulmonary nodules constitutes the most effective approach to reducing the mortality of LUAD. Despite the wide application of low‐dose computed tomography (LDCT) in...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202415689 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849471984298098688 |
|---|---|
| author | Chongyang Chen Keying Zhu Jing Wang Donghui Pan Xinyu Wang Yuping Xu Junjie Yan Lizhen Wang Min Yang |
| author_facet | Chongyang Chen Keying Zhu Jing Wang Donghui Pan Xinyu Wang Yuping Xu Junjie Yan Lizhen Wang Min Yang |
| author_sort | Chongyang Chen |
| collection | DOAJ |
| description | Abstract Lung adenocarcinoma (LUAD) constitutes a major cause of cancer‐related fatalities worldwide. Early identification of malignant pulmonary nodules constitutes the most effective approach to reducing the mortality of LUAD. Despite the wide application of low‐dose computed tomography (LDCT) in the early screening of LUAD, the identification of malignant pulmonary nodules by it remains a challenge. In this study, CEACAM6 (also called CD66c) as a potential biomarker is investigated for differentiating malignant lung nodules. Then, the CEACAM6‐targeting monoclonal antibody (mAb, tinurilimab) is radiolabeled with 89Zr and 131I for theranostic applications. In terms of diagnosis, machine learning confirms CEACAM6 as a specific extracellular marker for discrimination between LUAD and benign nodules. The 89Zr‐labeled mAb is highly specific uptake in CEACAM6‐positive LUAD via positron emission tomography (PET) imaging, and its ability to distinguish in malignant pulmonary nodules are significantly higher than that of 18F Fluorodeoxyglucose (FDG) by positron emission tomography/magnetic resonance (PET/MR) imaging. While the 131I‐labeled mAb serving as the therapeutic aspect has significantly suppressed tumor growth after a single treatment. These results proves that 89Zr/131I‐labeled tinurilimab facilitates the differential capacity of malignant pulmonary nodules and radioimmunotherapy of LUAD in preclinical models. Further clinical evaluation and translation of this CEACAM6‐targeted theranostics may be significant help in diagnosis and treatment of LUAD. |
| format | Article |
| id | doaj-art-814f6f5864da44e4b0e399afd324b86c |
| institution | Kabale University |
| issn | 2198-3844 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Science |
| spelling | doaj-art-814f6f5864da44e4b0e399afd324b86c2025-08-20T03:24:39ZengWileyAdvanced Science2198-38442025-06-011221n/an/a10.1002/advs.202415689A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with 89Zr/131I‐Labeled TinurilimabChongyang Chen0Keying Zhu1Jing Wang2Donghui Pan3Xinyu Wang4Yuping Xu5Junjie Yan6Lizhen Wang7Min Yang8NHC Key Laboratory of Nuclear Medicine Jiangsu Key Laboratory of Molecular Nuclear Medicine Jiangsu Institute of Nuclear Medicine Wuxi Jiangsu 214063 ChinaNHC Key Laboratory of Nuclear Medicine Jiangsu Key Laboratory of Molecular Nuclear Medicine Jiangsu Institute of Nuclear Medicine Wuxi Jiangsu 214063 ChinaWuxi Xishan NJU Institute of Applied Biotechnology Anzhen Street, Xishan District Wuxi 214101 ChinaNHC Key Laboratory of Nuclear Medicine Jiangsu Key Laboratory of Molecular Nuclear Medicine Jiangsu Institute of Nuclear Medicine Wuxi Jiangsu 214063 ChinaNHC Key Laboratory of Nuclear Medicine Jiangsu Key Laboratory of Molecular Nuclear Medicine Jiangsu Institute of Nuclear Medicine Wuxi Jiangsu 214063 ChinaNHC Key Laboratory of Nuclear Medicine Jiangsu Key Laboratory of Molecular Nuclear Medicine Jiangsu Institute of Nuclear Medicine Wuxi Jiangsu 214063 ChinaNHC Key Laboratory of Nuclear Medicine Jiangsu Key Laboratory of Molecular Nuclear Medicine Jiangsu Institute of Nuclear Medicine Wuxi Jiangsu 214063 ChinaNHC Key Laboratory of Nuclear Medicine Jiangsu Key Laboratory of Molecular Nuclear Medicine Jiangsu Institute of Nuclear Medicine Wuxi Jiangsu 214063 ChinaNHC Key Laboratory of Nuclear Medicine Jiangsu Key Laboratory of Molecular Nuclear Medicine Jiangsu Institute of Nuclear Medicine Wuxi Jiangsu 214063 ChinaAbstract Lung adenocarcinoma (LUAD) constitutes a major cause of cancer‐related fatalities worldwide. Early identification of malignant pulmonary nodules constitutes the most effective approach to reducing the mortality of LUAD. Despite the wide application of low‐dose computed tomography (LDCT) in the early screening of LUAD, the identification of malignant pulmonary nodules by it remains a challenge. In this study, CEACAM6 (also called CD66c) as a potential biomarker is investigated for differentiating malignant lung nodules. Then, the CEACAM6‐targeting monoclonal antibody (mAb, tinurilimab) is radiolabeled with 89Zr and 131I for theranostic applications. In terms of diagnosis, machine learning confirms CEACAM6 as a specific extracellular marker for discrimination between LUAD and benign nodules. The 89Zr‐labeled mAb is highly specific uptake in CEACAM6‐positive LUAD via positron emission tomography (PET) imaging, and its ability to distinguish in malignant pulmonary nodules are significantly higher than that of 18F Fluorodeoxyglucose (FDG) by positron emission tomography/magnetic resonance (PET/MR) imaging. While the 131I‐labeled mAb serving as the therapeutic aspect has significantly suppressed tumor growth after a single treatment. These results proves that 89Zr/131I‐labeled tinurilimab facilitates the differential capacity of malignant pulmonary nodules and radioimmunotherapy of LUAD in preclinical models. Further clinical evaluation and translation of this CEACAM6‐targeted theranostics may be significant help in diagnosis and treatment of LUAD.https://doi.org/10.1002/advs.20241568989Zr/131I‐labeled tinurilimabCEACAM6LUADmalignant pulmonary nodulesPET/MRtheranostics |
| spellingShingle | Chongyang Chen Keying Zhu Jing Wang Donghui Pan Xinyu Wang Yuping Xu Junjie Yan Lizhen Wang Min Yang A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with 89Zr/131I‐Labeled Tinurilimab Advanced Science 89Zr/131I‐labeled tinurilimab CEACAM6 LUAD malignant pulmonary nodules PET/MR theranostics |
| title | A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with 89Zr/131I‐Labeled Tinurilimab |
| title_full | A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with 89Zr/131I‐Labeled Tinurilimab |
| title_fullStr | A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with 89Zr/131I‐Labeled Tinurilimab |
| title_full_unstemmed | A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with 89Zr/131I‐Labeled Tinurilimab |
| title_short | A Novel Theranostic Strategy for Malignant Pulmonary Nodules by Targeted CECAM6 with 89Zr/131I‐Labeled Tinurilimab |
| title_sort | novel theranostic strategy for malignant pulmonary nodules by targeted cecam6 with 89zr 131i labeled tinurilimab |
| topic | 89Zr/131I‐labeled tinurilimab CEACAM6 LUAD malignant pulmonary nodules PET/MR theranostics |
| url | https://doi.org/10.1002/advs.202415689 |
| work_keys_str_mv | AT chongyangchen anoveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT keyingzhu anoveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT jingwang anoveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT donghuipan anoveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT xinyuwang anoveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT yupingxu anoveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT junjieyan anoveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT lizhenwang anoveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT minyang anoveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT chongyangchen noveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT keyingzhu noveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT jingwang noveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT donghuipan noveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT xinyuwang noveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT yupingxu noveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT junjieyan noveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT lizhenwang noveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab AT minyang noveltheranosticstrategyformalignantpulmonarynodulesbytargetedcecam6with89zr131ilabeledtinurilimab |